Hyperactivation of P2X7 receptors as a culprit of COVID-19 neuropathology

Deidiane Elisa Ribeiro1 · Ágatha Oliveira-Giacomelli1 · Talita Glaser1 · Vanessa F. Arnaud-Sampaio1 · Roberta Andrejew1 · Luiz Dieckmann2 · Juliana Baranova1 · Claudiana Lameu1 · Mariusz Z. Ratajczak3 · Henning Ulrich1

Received: 22 July 2020 / Revised: 4 November 2020 / Accepted: 17 November 2020 / Published online: 16 December 2020
© The Author(s), under exclusive licence to Springer Nature Limited 2020

Abstract
Scientists and health professionals are exhaustively trying to contain the coronavirus disease 2019 (COVID-19) pandemic by elucidating viral invasion mechanisms, possible drugs to prevent viral infection/replication, and health cares to minimize individual exposure. Although neurological symptoms are being reported worldwide, neural acute and long-term consequences of SARS-CoV-2 are still unknown. COVID-19 complications are associated with exacerbated immunoinflammatory responses to SARS-CoV-2 invasion. In this scenario, pro-inflammatory factors are intensely released into the bloodstream, causing the so-called “cytokine storm”. Both pro-inflammatory factors and viruses may cross the blood–brain barrier and enter the central nervous system, activating neuroinflammatory responses accompanied by hemorrhagic lesions and neuronal impairment, which are largely described processes in psychiatric disorders and neurodegenerative diseases. Therefore, SARS-CoV-2 infection could trigger and/or worse brain diseases. Moreover, patients with central nervous system disorders associated to neuroimmune activation (e.g. depression, Parkinson’s and Alzheimer’s disease) may present increased susceptibility to SARS-CoV-2 infection and/or achieve severe conditions. Elevated levels of extracellular ATP induced by SARS-CoV-2 infection may trigger hyperactivation of P2X7 receptors leading to NLRP3 inflammasome stimulation as a key mediator of neuroinvasion and consequent neuroinflammatory processes, as observed in psychiatric disorders and neurodegenerative diseases. In this context, P2X7 receptor antagonism could be a promising strategy to prevent or treat neurological complications in COVID-19 patients.

Introduction
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first identified in December 2019 as the infectious agent of coronavirus disease 2019 (COVID-19).
COVID-19 complications are widely associated with exacerbated immunoinflammatory responses upon SARS-CoV-2 lung invasion. In this scenario, pro-inflammatory factors are intensely released, the so-called “cytokine storm”, which enter the bloodstream, and reach other organs (Fig. 1A) [9]. In this sense, both pro-inflammatory factors and viruses can cross the blood–brain barrier (BBB) and enter the central nervous system (CNS), initiating a neuroinflammatory process [10]. BBB permeability is increased in patients with neurodegenerative diseases, which could facilitate SARS-CoV-2 neuroinvasion. In addition, the neuroinflammatory insult could increase susceptibility to neurodegeneration in patients who are not yet suffering from these diseases. While confirmation of this hypothesis may take years, possible long-term consequences of COVID-19 need to be highlighted.

Neurotropism of human coronaviruses has already been demonstrated in small animals and in autopic studies of brains infected with the severe acute respiratory syndrome coronavirus (SARS-CoV) [11], which was responsible for the severe acute respiratory syndrome (SARS) outbreak during 2002–2003. Image studies [12, 13] and postmortem examination [14] of the brain of COVID-19 patients also revealed hemorrhagic lesions accompanied by neuronal injury and neuroinflammation signals. These brain pathologies are described as both etiological factors and consequences of psychiatric disorders and neurodegenerative diseases [15]. Therefore, it is plausible to suggest that patients with COVID-19 are prone to develop neurological disorders, as well as patients suffering from these conditions are more susceptible to SARS-CoV-2 infection. In this context, understanding the mechanisms underlying

---

**Fig. 1 Possible routes of SARS-CoV-2 infection of the central nervous system and cytokine storm involvement.**

A In the lung, SARS-CoV-2 may infect type I and II pneumocytes (dark and light blue, respectively) and proliferate in these cells. SARS-CoV-2 invades type I pneumocytes following binding to TMPPRSS2 and possibly CD147 receptors, whereas invasion of type II pneumocytes additionally involves binding to ACE2 [171, 172]. The distressed cells release pro-inflammatory factors and DAMPs, such as ATP, which recruit macrophages (green) by activating P2X7 receptors. These macrophages increase the release of cytokines, chemokines, and ATP, inducing the cytokine storm. ATP could also activate P2X7 receptors in type I pneumocytes. These pro-inflammatory factors, as well as the virus, reach the circulatory system and can induce inflammatory responses in other tissues, in part through the activation of P2X7 receptors by released ATP. B In the neuronal retrograde pathway, the virus infects peripheral neurons and uses synaptic connections to reach the CNS. In the transcribrial pathway, SARS-CoV-2 can multiply in sustentacular cells (pink) of the nasal cavity, using ACE2 and TMPRSS2 receptors for infection or in olfactory sensory neurons (purple) following binding to CD147 receptors. Thus, the virus uses these neurons to reach the CNS olfactory bulb (yellow) and infect cells using ACE2 receptors [173]. Sustentacular cells express P2X7 receptors [174]. C Once in the bloodstream, the virus can reach and infect blood–brain barrier (BBB) endothelial cells (pink), through binding to ACE2 and CD147 [175], and perivascular astrocytes (green), through binding to ACE2 [172]. In COVID-19, the BBB shows increased permeability due to the inflammatory process and death of endothelial cells and astrocytes, possibly resulting from P2X7 receptor activation. Although not yet confirmed, the virus could infect monocytes (purple) using CD147 receptors [176], which in turn can pass the BBB. Inside the CNS, the virus can infect neurons (blue) and other neural cell, by binding to ACE2 [173] and possibly to CD147 [177]. Moreover, cytokines present in circulating blood can also reach the CNS through BBB breaches and induce neuroinflammation, sensitizing the brain. Created with BioRender.com.
COVID-19 neuropathology is essential for the development of therapeutic strategies. Hyperactivation of P2X7 receptors is closely related to inflammatory processes since they are stimulated by ATP released from distressed cells and induce inflammasome activation [16–18]. P2X7 receptors are ATP-gated ion channels widely expressed in the CNS [19], and their activation induced by viral infection leads to molecular (mainly neuroimmune response activation, reactive oxygen species (ROS) formation, and glutamate release) and behavioral alterations [17, 20] as well as to mental disorders [21].

Based on this, we postulate that both, neuroinvasion through the BBB and hyperstimulation of neuroimmune responses observed during COVID-19 infection, are mediated by hyperactivation of the P2X7 receptor, possibly through NLRP3 inflammasome stimulation. This cascade could lead to COVID-19-associated psychiatric disorders and neurodegenerative diseases. Thus, P2X7 receptor antagonism would be a promising strategy to prevent or treat neurological complications in infected patients. This concept will be discussed in detail in our review.

**Neurological symptoms in COVID-19**

An increasing number of studies reports the manifestation of neurological symptoms in patients with COVID-19. As reviewed by Pezzini and Padovani, neurological manifestations affect between 4.2 and 100% of studied patients; dizziness (prevalent in 7.6–46.1%), headache (5.1–77.1%), impaired consciousness (9.5–64.1%), and seizures (1.2–26%) [22]. Noteworthy, in COVID-19 patients presenting at least one neurological symptom, the prevalence of acute stroke (2.9–76.8%), confusion (14.2–65%), and encephalitis (0–27.9%) stands out. COVID-19 patients also present other nervous system symptoms, such as impaired taste (10–19.2%) and smell (21.7%), dysautonomia (4.3–12%), and acute inflammatory demyelinating polyneuropathy (0–16.2%) [22].

Together with an acute cerebrovascular disorder, all symptoms are correlated with the consequences of strokes or micro-strokes [23]. Moreover, reported impaired olfaction could be due to CNS invasion or direct damage of olfactory sensory neurons in the nasal cavity [24].

Psychiatric symptoms are being reported in COVID-19 patients, healthcare workers and in the general population. Table 1 summarizes meta-analysis and systematic reviews on these topics. The studies were selected after searching the PubMed data base on September 20, 2020 for the terms: “(COVID-19 or SARS-CoV-2 or severe acute respiratory syndrome coronavirus 2) and (mental health or psychological health or depression or anxiety or PTSD or PTSS or post-traumatic stress disorder or post-traumatic stress symptoms)”.

Although studies on psychiatric symptoms accompanying SARS-CoV-2 illness need further investigation, the available data indicate that COVID-19 patients mainly present depressive symptoms (42–65%), anxiety (37–47%), and PTSS (93–96%). Noteworthy, stress caused by the pandemic situation (e.g., social isolation, fear of infection, and financial instability) may also induce depressive symptoms (14.6–48.3%), anxiety (6.33–50.9%), and PTSS (7–53.8%) in the general population. The stressful situation of healthcare workers, specially the fear to infect relatives, may lead to depressive symptoms (12.2–26.3%), anxiety (13–29%), and PTSS (3–20.7%) as well.

In this scenario, the following proposals are raised and require additional studies: (1) alterations induced by stress exposure (e.g., immune hyperactivation) could both facilitate SARS-CoV-2 infection as well as aggravate COVID-19 symptoms; (2) neurological symptoms are probably not specifically related to SARS-CoV-2 infection, but they are a general consequence of infectious disorders (which include sickness behavior), stressful events (pandemic situation), and/or immune response hyperactivation (“cytokine storm”); (3) genetic and/or environmental factors affect the development of neurological symptoms, as these responses highly vary across the population. Clarifying these issues would improve the understanding on SARS-CoV-2 infection and direct the search for treatments.

**SARS-CoV-2 neuroinvasion**

COVID-19 patients are presenting neurological symptoms worldwide. Although brain analysis of these patients is not being widely performed, a study detected SARS-CoV-2 in 8 of 21 postmortem brain tissues, based on reverse transcriptase polymerase chain reaction [25]. Moreover, neuroinvasion capability of SARS-CoV-2 was observed in human brain organoids, especially in neuronal cells, such as neural progenitor and radial glial cells, accompanied by increased cell death [26]. The same study found positive staining for SARS-CoV-2 spike protein in the brain of three COVID-19 patients, with different expression patterns and staining intensities [26]. Neuroinvasion potential of SARS-CoV-2 was demonstrated in mice expressing human ACE2 and correlated with increased mortality independent from respiratory infection [26]. SARS-CoV-2 also seems to invade infants’ brains, since immunohistochemical analysis of the postmortem brain of a 1-year-old infant showed positive staining in the choroid plexus, ventricles and cerebral cortex [27]. Remarkably, a case report demonstrated the presence of SARS-CoV-2 viral particles in neural tissue and brain capillary...
Table 1 Summary of systematic reviews and meta-analysis of psychiatric symptoms exhibited by the general population, healthcare workers, COVID-19 patients, and psychiatric patients due to the COVID-19 pandemic outbreak.

| Psychiatric outcome          | Prevalence % (95% CI) | Total sample size | Sample location                     | Studies included | Reference |
|-----------------------------|-----------------------|-------------------|------------------------------------|------------------|-----------|
| **Depression**              |                       |                   |                                    |                  |           |
| Overall                     | 26% (20–33%)          | 173,662           | China, Iran, Italy, Singapore, Vietnam | 50               | [178]     |
| General population          | 24% (14–36%)          |                   |                                    |                  |           |
| Healthcare workers          | 25% (19–32%)          |                   |                                    |                  |           |
| COVID-19 patients           | 42% (28–57%)          |                   |                                    |                  |           |
| **Anxiety**                 |                       |                   |                                    |                  |           |
| Overall                     | 26% (21–31%)          |                   |                                    |                  |           |
| General population          | 26% (20–32%)          |                   |                                    |                  |           |
| Healthcare workers          | 24% (16–32%)          |                   |                                    |                  |           |
| COVID-19 patients           | 37% (19–57%)          |                   |                                    |                  |           |
| **Psychological distress**  |                       |                   |                                    |                  |           |
| Overall                     | 34% (27–42%)          |                   |                                    |                  |           |
| General population          | 26% (21–32%)          |                   |                                    |                  |           |
| Healthcare workers          | 41% (19–65%)          |                   |                                    |                  |           |
| **Stress**                  |                       |                   |                                    |                  |           |
| Overall                     | 34% (20–50%)          |                   |                                    |                  |           |
| General population          | 36% (5–75%)           |                   |                                    |                  |           |
| Healthcare workers          | 33% (19–50%)          |                   |                                    |                  |           |
| **Post-traumatic stress symptoms** |                   |                   |                                    |                  |           |
| Overall                     | 27% (12–45%)          |                   |                                    |                  |           |
| General population          | 15% (4–31%)           |                   |                                    |                  |           |
| Healthcare workers          | 13% (11–16%)          |                   |                                    |                  |           |
| COVID-19 patients           | 96% (95–97%)          |                   |                                    |                  |           |
| **Poor sleep quality**      |                       |                   |                                    |                  |           |
| Overall                     | 40% (25–57%)          |                   |                                    |                  |           |
| General population          | 34% (12–60%)          |                   |                                    |                  |           |
| Healthcare workers          | 43% (28–59%)          |                   |                                    |                  |           |
| COVID-19 patients           | 82% (66–92%)          |                   |                                    |                  |           |
| **Insomnia**                |                       |                   |                                    |                  |           |
| Overall                     | 30% (12–52%)          |                   |                                    |                  |           |
| General population          | 7% (7–8%)             |                   |                                    |                  |           |
| Healthcare workers          | 37% (32–42%)          |                   |                                    |                  |           |
| **Depression**              |                       |                   |                                    |                  |           |
| General population          | 14.6–48.3%            | 93,569            | China, Denmark, Nepal, Spain, Turkey, USA | 19               | [179]     |
| Anxiety                     |                       |                   |                                    |                  |           |
| General population          | 6.33–50.9%            |                   |                                    |                  |           |
| Post-traumatic stress disorder |                   |                   |                                    |                  |           |
| General population          | 7–53.8%               |                   |                                    |                  |           |
| Psychological distress      |                       |                   |                                    |                  |           |
| General population          | 34.43–38%             |                   |                                    |                  |           |
| Stress                      |                       |                   |                                    |                  |           |
| General population          | 8.1–81.9%             |                   |                                    |                  |           |
| **Depression**              |                       |                   |                                    |                  |           |
| Healthcare workers vs. professionals from other areas | 12.2% vs. 9.5% (OR = 1.3246; 95% CI 1.0930–1.6053) | 17,330 | China | 8 | [180] |
| Anxiety                     |                       |                   |                                    |                  |           |
| Healthcare workers vs. professionals from other areas | 13.0% vs. 8.5% (OR = 1.6152; 95% CI 1.3283–1.9641) | 63,439 | China, India, Iran, Iraq, Italy, Japan, Nepal, Nigeria, Spain, UK | 17 | [181] |
| **Stress**                  |                       |                   |                                    |                  |           |
| General population          | 29.6% (24.3–35.4%)    |                   |                                    |                  |           |
| Asia                        | 27.9% (19.7–37.8%)    |                   |                                    |                  |           |
| Europe                      | 31.9% (23.1–42.2%)    |                   |                                    |                  |           |
| Anxiety                     |                       |                   |                                    |                  |           |
| General population          | 31.9% (27.5–36.7%)    |                   |                                    |                  |           |
| Asia                        | 32.9% (28.2–37.9%)    |                   |                                    |                  |           |
| Europe                      | 23.8% (16.2–33.5%)    |                   |                                    |                  |           |
| Depression                  |                       |                   |                                    |                  |           |
| General population          | 33.7% (27.5–40.6%)    |                   |                                    |                  |           |
| Asia                        | 35.3% (27.3–44.1%)    |                   |                                    |                  |           |
endothelium of a Parkinson’s disease patient, which was associated with the worsening of neurological symptoms [28].

However, the mechanism of SARS-CoV-2 infection of the brain is still unknown. Invasion routes of the CNS by other viruses include: (a) the hematogenous route, in which

| Table 1 (continued) |
|---------------------|
| Psychiatric outcome | Prevalence % (95% CI) | Total sample size | Sample location | Studies included | Reference |
|---------------------|
| Europe              | 32.4% (21.6–45.5%)     | N.R.              | N.R.            | 40              | [182]     |
| Healthcare workers exposed to SARS/MERS/COVID-19 | 37.8% (28.4–48.2%)     | 162,639           | Argentina, Brazil, Chile, China, Denmark, Greece, India, Iran, Israel, Italy, Japan, Mexico, Pakistan, Singapore, Spain, Turkey, Vietnam | 62       | [183]     |
| Burnout             | 34.4% (19.3–53.5%)     |                  |                 |                 |           |
| Anxiety             | 29.0% (14.2–50.3%)     |                  |                 |                 |           |
| Depressive symptoms | 26.3% (12.5–47.1%)     |                  |                 |                 |           |
| Post-traumatic stress disorder | 20.7% (13.2–31%) | 33,062 | China, Singapore | 12 | [184] |
| Anxiety             | Overall                | 33% (28–38%)      |                 |                 |           |
| General population  | 32% (25–39%)           |                  |                 |                 |           |
| General population—Italy | 81% (80–83%)         |                  |                 |                 |           |
| Healthcare workers  | 26% (18–34%)           |                  |                 |                 |           |
| Healthcare workers—Singapore | 7% (5–9%)    |                  |                 |                 |           |
| Healthcare workers—Italy | 57% (52–63%)       |                  |                 |                 |           |
| Psychiatric patients with moderate-to-severe anxiety COVID-19 patients | 24% (14–33%) | 65% (51–77%) | 16% (15–17%) | 3% (2–4%) | 93% (92–95%) | 23.21% (17.77–29.13%) | 20.92% (11.86–31.65%) | 29.06% (20.21–38.78%) |
| COVID-19 patients with type 2 diabetes—India | 47% (34–61%) | 1048 | D. E. Ribeiro et al. | 1048 | D. E. Ribeiro et al. |
| General population  | 27% (22–33%)           |                  |                 |                 |           |
| General population—Italy | 67% (65–69%)         |                  |                 |                 |           |
| Healthcare workers  | 25% (17–33%)           |                  |                 |                 |           |
| Healthcare workers—Singapore | 9% (7–12%)    |                  |                 |                 |           |
| Healthcare workers—China | 51% (48–53%)       |                  |                 |                 |           |
| Psychiatric patients with moderate-to-severe depression COVID-19 patients—China | 22% (13–32%) | 65% (51–77%) | 16% (15–17%) | 3% (2–4%) | 93% (92–95%) | 23.21% (17.77–29.13%) | 20.92% (11.86–31.65%) | 29.06% (20.21–38.78%) |
| Depression           | Overall                | 28% (23–32%)      |                 |                 |           |
| General population  | 27% (22–33%)           |                  |                 |                 |           |
| General population—Italy | 67% (65–69%)         |                  |                 |                 |           |
| Healthcare workers  | 25% (17–33%)           |                  |                 |                 |           |
| Healthcare workers—Singapore | 9% (7–12%)    |                  |                 |                 |           |
| Healthcare workers—China | 51% (48–53%)       |                  |                 |                 |           |
| Psychiatric patients with moderate-to-severe depression COVID-19 patients—China | 22% (13–32%) | 65% (51–77%) | 16% (15–17%) | 3% (2–4%) | 93% (92–95%) | 23.21% (17.77–29.13%) | 20.92% (11.86–31.65%) | 29.06% (20.21–38.78%) |
| Distress             | Overall                | 35% (23–47%)      |                 |                 |           |
| Stress               | Overall                | 40% (20–60%)      |                 |                 |           |
| Insomnia             | Overall                | 32% (25–39%)      |                 |                 |           |
| Post-traumatic stress symptoms/disorders | General population | 16% (15–17%) | 3% (2–4%) | 93% (92–95%) | 23.21% (17.77–29.13%) | 20.92% (11.86–31.65%) | 29.06% (20.21–38.78%) |
| Healthcare workers  | 3% (2–4%)              |                  |                 |                 |           |
| COVID-19 patients    | 93% (92–95%)           |                  |                 |                 |           |
| Anxiety              | Healthcare workers     | 23.21% (17.77–29.13%) | 20.92% (11.86–31.65%) | 29.06% (20.21–38.78%) | 23.21% (17.77–29.13%) | 20.92% (11.86–31.65%) | 29.06% (20.21–38.78%) |
| Depression           | Healthcare workers     | 22.93% (13.16–34.38%) | 20.34% (11.57–30.75%) | 26.87% (15.39–40.09%) | 22.93% (13.16–34.38%) | 20.34% (11.57–30.75%) | 26.87% (15.39–40.09%) |
| Insomnia             | Healthcare workers     | 34.32% (27.45–41.54%) |                  |                 | 34.32% (27.45–41.54%) | 20.92% (11.86–31.65%) | 29.06% (20.21–38.78%) |

CI Confidence interval, OR Odds ratio, N.R. Not reported
viruses use the bloodstream to reach and invade epithelial cells from the BBB or the blood–cerebrospinal fluid barrier, or use leukocytes as a vector to enter the CNS; (b) the neuronal retrograde route, in which viruses invade peripheral neurons and reach CNS, including the transcriptsribrial route, using olfactory sensory neurons in the nasal cavity (Fig. 1B) [10].

In the hematogenous route, the virus must be capable of crossing the BBB (Fig. 1C). This barrier is composed of endothelial cells, pericytes, and astrocytes. The restricted permeability of the BBB is a reflex of the connection between brain microvascular endothelial cells and tight cell–cell junctions. The BBB is disrupted under inflammatory conditions [29, 30]. In the “Trojan horse” mechanism of CNS invasion, infected leukocytes pass the BBB. This mechanism is observed for HIV, and since SARS-CoV can infect immune cells, it is likely that SARS-CoV-2 also uses this route toward the CNS [10]. Viral infection also affects BBB integrity by different mechanisms, including phosphorylation of tight junction proteins, disruption of the basal lamina or of the actin cytoskeleton, or by invading BBB-epithelial cells and furthermore astrocytes [10, 31].

Evidence of CNS invasion through neuronal retrograde routes was reported for coronaviruses, such as HCoV-OC43, HEV67 and avian bronchitis virus [32]. Once respiratory and digestive tracts of animals were infected, coronaviruses invaded peripheral neurons and passed through synaptic connections until they reached medullary neurons and subsequently other neurons and glial cells of the CNS [32]. As the main entry route of SARS-CoV-2 in humans, cells from the nasal cavity could be susceptible to viral infection and replication. Studies reported that human olfactory sustentacular cells express both ACE2 and TMPRSS2 virus receptors [33]. Although current literature data reports that human olfactory sensory neurons do not express these proteins, they express CD147 that could allow SARS-CoV-2 neuroinvasion (Fig. 1) [33, 34]. In fact, SARS-CoV, MERS-CoV, and HCoV-OCR43 were able to invade the murine CNS using the transcriptsribrial route, infecting olfactory sensory neurons of nasal cavity, and passing to other neural cells, indicating that SARS-CoV-2 could use the same mechanism [24, 35–37].

Inflammation and CNS-related lethality of COVID-19

Severe COVID-19 patients commonly develop the Acute Respiratory Distress Syndrome [38], which is characterized by inflammatory injury to the alveoli–capillary membrane, leading to lung over-permeability and increased pulmonary edema fluid into the airspaces, resulting in the lack of respiratory capacity [39]. This overreaction of the innate immune system against viral infection induces the so-called “cytokine storm”, comprising of: (1) the release of large amounts of several pro-inflammatory cytokines (interferons IFNα and IFNγ, interleukins [IL-1β, IL-6, IL-12, IL-18 and IL-33], tumor necrosis factor [TNF]-α, and transforming growth factor [TGF]-β) and chemokines (CXCL10, CXCL8, CXCL9, CCL2, CCL3, CCL5); (2) release of renin–angiotensin aldosterone system (RAAS) mediators and increasing blood levels of angiotensin II (Ang II); and lately (3) amplification of the innate immune system response and activation of its major humoral arm, the complement cascade (ComC) [40].

Novel evidence indicates that COVID-19-released mediators merge on a common pathway, upregulating cytosolic danger sensing pattern recognition receptor, which is part of a multiprotein complex of the innate immune system that is called inammamasome, and recognizes both pathogen-associated molecular patterns and self-derived danger-associated molecular patterns (DAMPs) or alarmines [41].

Importantly, upon inammamasome protein assembly and activation, pro-caspase 1 protein is cleaved to functional caspase 1, whose main function is the conversion of the inactive and intracellularly stored pro-inflammatory cytokines, pro-IL-1β and pro-IL-18, into their active forms that are released from cells. This release is facilitated by creating gasdermin D (GSDMD) pore channels in cell membranes. In addition to these two cytokines, gasdermin D channels also mediate the release of several biologically active DAMPs or alarmines, including extracellular ATP, high mobility group protein B1, and S100 calcium-binding proteins A8 and A9 (S100B/9a) [42].

There are various inammamasome subtypes. The NLRP3 inammamasome protein complex is usually involved in virus infections and consists of NLRP3 protein, apoptosis-associated speck-like protein containing a CARD (ASC) and pro-caspase-1, and remains in the cytosol in steady-state conditions in an inactive form. Upon activation, it becomes a multiprotein aggregate composed of several NLRP3 molecules (speck complexes), each containing NLRP3 protein, ASC, and pro-caspase 1 [41].

We consider the NLRP3 inammamasome as a trigger of the cytokine storm, as seen in COVID-19 patients, that may be induced by P2X7 receptor activation, including in the brain (Fig. 2). Once SARS-CoV-2 spike protein interacts with ACE2, macrophages/microglia cells can potentiate the immune response through the cleavage of fragments complement component 3a and 5a (C3a and C5a, respectively) and non-lytic C5b-C9 membrane attack complex by ComC, thus activating the NLRP3 inammamasome [41]. Moreover, NLRP3 inammamasome activation during COVID-19 infection is usually triggered by Ang II, which binds to the angiotensin type 1 receptor (AT1R), leading to vessel contraction and increasing blood pressure. In normal conditions, Ang II is converted by the ACE2 receptor into angiotensin 1–7 (Ang 1–7) [43]. Ang II activates the AT1R,
Fig. 2 P2X7 receptor-mediated neuroinflammatory implications of SARS-CoV2 invasion in the CNS. A SARS-CoV-2 may alter brain function by reaching the central nervous system (described in Fig. 1) and/or through the cytokine storm-mediated effects. The result is a neuroinflammatory process characterized by microglia (pink) hyper-activation, astrocyte (green) stimulation, and demyelination (yellow caps) of neurons (blue). In addition, the cytokine storm induces blood-clot formation and increased capillary (red) permeability resulting in embolic and hemorrhagic strokes, respectively. B A molecular view, the distressed cells release pro-inflammatory cytokines (yellow circles) and ATP (red circles). ATP activates P2X7 receptors (red) expressed mainly in microglia (pink) and astrocytes (green) resulting in increased Ca\(^{2+}\) influx and glutamate (purple circles) release. Glutamate activates NMDA receptors expressed in nerve terminals (blue), which enable Ca\(^{2+}\)-dependent exocytosis of ATP and more glutamate release. In this way, an auto regenerative loop is formed causing a massive release of these neurotransmitters augmenting excitotoxicity and cell death. In the postsynaptic neuron (blue), increased [Ca\(^{2+}\)]\(_i\) leads to Ca\(^{2+}\)-calmodulin (CaM) complex formation and consequent nNOS activation. NO production mediates neurotoxicity via several mechanisms. NO interacts with the iron–sulfur centers in the mitochondrial electron transport chain impairing cellular energy production. NO also produces reactive nitrogen species and reactive oxygen species (ROS). Reaction of NO and superoxide ion (O\(_2\)\(^{-}\), formed by nNOS under low arginine concentrations) generates peroxynitrite (ONOO\(^{-}\)) and peroxynitrous acid (ONOOH). These free radicals can also decompose into other reactive species, such as hydroxyl radical and peroxides, inducing fibrosis, increased ROS release, vasoconstriction, and gut dysbiosis. In contrast, Ang 1–7 binds to Mas receptors (MasR), thus protecting against fibrotic formation, presenting antioxidant and vasodilatory effects. The problem with the conversion of Ang II into Ang 1–7 is that the ACE2 enzyme expressed on surface of cells is a COVID-19 receptor and is blocked or downregulated after binding of virus or even shed from the cell surface [43]. Extracellular ATP can also robustly trigger activation of the NLRP3 inflammasome through P2X7 receptor activation. In addition, ATP is also released into the extracellular milieu upon NLRP3 inflammasome activation, promoting a strong positive feedback loop [44]. SARS-CoV-2-induced systemic inflammatory responses may also result in endothelial damage and consequently increased production of thrombin by inflammatory cytokines during sepsis in a bidirectional way, because inflammation activates coagulation, and coagulation augments inflammatory activity [45]. In this scenario, active inflammatory cells expressing specific protease activated receptors
(PAR1–4) bind to thrombin, while the Toll-like receptor 4 interacts with fibrin. Supporting these events, patients in particular at younger age are often diagnosed with stroke and cardiovascular complications.

Recent evidence indicates that the occurrence of psychiatric disorders in patients is linked to “sterile” inflammation of the brain that may be initiated locally by some stressors affecting nervous tissue or occurs due to a systemic inflammation process [17, 46]. This is supported by the observation that several inflammatory mediators and markers are detected in the peripheral blood of patients with psychiatric and neurodegenerative disorders [17, 46], which could worsen prognoses for COVID-19 outcome. Moreover, clinical data describe correlations between systemic chronic inflammatory processes and psychiatric disorders. This may also explain, why some reported anti-inflammatory treatment strategies ameliorate neurodegeneration [17, 46]. In agreement, pathological increase of AngII-AT1R-mediated activation of NLRP3 inflammasome may initiate psychosis. We believe that bioactive inflammatory mediators released during the cytokine storm, such as extracellular ATP, affect the CNS and may lead to its impairment, mainly through P2X7 receptor activation, as we discuss in the following.

**Probable P2X7 receptor roles in COVID-19 processes**

The P2X7 receptor is widely expressed through the body [47], including in immune [48], lung [49], and CNS cells, mainly microglia and oligodendrocytes [50–52], whereas its expression in neurons and astrocytes is still under discussion [50, 51, 53–60]. During the progress of infection, ATP release may result from the NLRP3 inflammasome response to COVID-19 infection (i) after virus spike protein interaction with the virus entry receptor ACE2, (ii) due to elevated level of Ang II observed in infected patients, or (iii) in response to activated ComC mediators [61]. Consequently, P2X7 receptors are activated, increasing inflammatory responses as well as modulating RAAS-related pathways and BBB permeability, as we discuss in the following.

**P2X7 receptor role in inflammation**

The P2X7 receptor is a trimeric ionotropic receptor that belongs to the P2X family of purinergic receptors, presenting low affinity for ATP (EC50 around 0.3–1.8 mM) and, under prolonged stimulation, can form pores allowing the passage of large hydrophilic molecules [62–64]. Activation of P2X7 receptor elicits rapid K⁺ efflux as well as Ca²⁺ and Na⁺ influx, resulting in the stimulation of several intracellular intermediators, as PLC, PLA2, PKC, MAPK, PI3K, ERK1/2 and p38, among others [65]. Consequently, P2X7 receptor activation is associated with numerous cellular functions, as plasma membrane blebbing, phosphatidyserine exposure in the membrane, formation of ROS, interleukin secretion, cell death and proliferation [65, 66].

ATP concentration is present in the nanomolar range in extracellular space of healthy tissues [67]. Conversely, in a disease state as infection or brain disease, extracellular ATP levels largely increase and activate P2X7 receptors [68–70]. Consequently, pore formation results in enhanced release of ATP and establishes a positive feedback in pathological conditions. In these circumstances, ATP may act as DAMP, which activates the nuclear transcription factor NF-κB resulting in expression upregulation of pro-IL-1β and pro-IL-18 and the NLRP3 protein [16, 71]. In addition, P2X7 receptor activation triggers K⁺ efflux, a signal required for efficient NLRP3 inflammasome stimulation [72]. Consequently, there is an activation of caspase-1 and maturation of IL-1β and IL-18, resulting in pro-inflammatory cytokine release [16, 20, 52, 71, 73]. The P2X7 receptor is a major activator of the NLRP3 inflammasome in several cell types [16], including macrophages and microglial cells [72, 74–76]. Moreover, P2X7 receptor activation also promotes the release of other inflammatory mediators such as IL-6, TNF-α, CCL2, CCL3, and CXCL2 [77–80].

In fact, the role of P2X7 receptor as a modulator of inflammatory response is well-established [16, 70]. It was already reported its capacity to modulate acute and chronic infection [81, 82], inflammatory diseases [82], sepsis [83, 84], neuropathic pain [85], and T-cell activation [86]. In addition, P2X7 receptor expression deletion appears to be beneficial in case of acute lung injury, asthma, lung inflammation, and fibrosis [87–91]. Remarkably, P2X7 receptor activation increases neuroinflammatory responses, which have been associated with neurodegenerative diseases, psychiatric disorders and stroke [21, 92–95], as further discussed.

Cytokine storms have been reported in several viral infections [96], including SARS-CoV-2 [9, 97]. Patients infected with SARS-CoV-2 present elevated levels of IL-6, IL-10, IL-1β, INF-γ, CCL2, TNF-α, CXCL10, CCL7, IL-1 receptor antagonist and IL-2 receptor, supposedly associated with disease severity [9, 98–105]. Considering the P2X7 receptor role in inflammation, its activation may be involved in the cytokine storm observed in COVID-19 by stimulating NLRP3 inflammasome, overshooting inflammation with extensive cytokine release, affecting coagulation and leading to diffuse lung edema and infiltration by immune cells and inflammatory cytokines [106]. As discussed by Di Virgilio et al. [106], many processes associated with lung impairment, as seen in COVID-19 patients, are mediated by P2X7 receptors [16]. The massive ATP release following lung mononuclear phagocytes
invasion by SARS-CoV-2 can activate P2X7 receptors of antigen-presenting cells and macrophages, increasing cytokine, chemokine and ATP secretion [16]. In addition, P2X7 receptor knockout mice submitted to a model of lung fibrosis revealed reduced infiltration of inflammatory cells, cytokine release, apoptosis, and fibrosis, while P2X7 receptor agonists increased these deleterious processes [88, 107]. Therefore, we hypothesize that the P2X7 receptor activation is involved in the cytokine storm and associated lung and brain inflammation caused by SARS-CoV-2 infection.

P2X7 receptors and the renin–angiotensin system

The P2X7 receptor, as a central player in inflammation, participates in viral infections. Exerting mostly proinflammatory roles [20], the P2X7 receptor is important for pathogen elimination [108], but on the other hand, its activation may be detrimental to the host due to the induction of exacerbated inflammatory responses. Protective roles of P2X7 receptor activation have been described, for instance, against vesicular stomatitis virus, Newcastle disease virus, murine leukemia virus and HSV virus infections [108]. Controversially to the above-cited beneficial P2X7 receptor-mediated viral elimination, this receptor was described to even facilitate virion release from HIV-infected macrophages in an exocytosis-dependent way [109]. Moreover, P2X7 receptor activation exacerbated inflammation, enhanced tissue damage, increased mortality, and worsened lung pathology involving P2X7 receptor expression or activation, such as observed in several other studies with e.g., influenza A virus [110] and adenovirus [111].

Importantly, the P2X7 receptor triggers pathways related to the functioning of the RAAS, importantly implicated in COVID-19 pathology. RAAS mediates key events of the disease, including viral entry in the cell [112, 113], inflammation, and lung fibrosis [114]. The pressor axis of RAAS bases on Ang II actions through the activation of AT1R. ACE is responsible for the cleavage of angiotensin I into Ang II, and Ang II levels are counterbalanced by the depressor axis that degrades Ang II into Ang 1,7 through ACE2 activity. Finally, Ang 1,7 activates MasR [115]. ACE2, independent from its enzymatic activity, serves as SARS-CoV-2 entry route in human cells, but as this enzyme is internalized following virus binding, its enzyme function is lost [6, 116]. Consequently, Ang 1,7 that would exert beneficial effects against CNS damage and neurological deficits [115] is not formed, prevailing Ang II actions mediated by the AT1R promoting fibrosis, lung injury, and importantly neuroinflammation [115].

In fact, the balance between the pressor and depressor axis of RAAS is implicated in neurodegenerative and psychiatric disorders, as carefully reviewed elsewhere [115, 117]. Briefly, components of the depressor axis correlate to enhanced cognition and cell survival in the brain, orchestrating antioxidant, and anti-inflammatory responses. In agreement, inhibition of the pressor axis attenuates cognitive deficits observed in aging, Alzheimer’s disease, Parkinson’s disease, vascular cognitive impairment and poststroke cognitive impairment [117]. Since the P2X7 receptor is also involved in lung damage [87–89], neurodegenerative and psychiatric disorders [92, 95, 118], the hypothesis is reasonable that inhibition of this receptor might decrease pathological traits mediated by the RAAS pressor axis and protect against brain and lung injury in COVID-19 patients. Indeed, evidence demonstrates that P2X7 receptor blockade prevents Ang II-triggered pro-inflammatory responses [119]. Furthermore, in rats with diabetic nephropathy, P2X7 receptor expression decreased ACE activity and Ang II levels [120], which might increase ACE2 expression [43] and counteract SARS-CoV-2-induced inflammatory exacerbation.

Conciliating all these findings, we highlight that the blockade of P2X7 receptors might prevent inflammatory exacerbation both, through its direct actions in inflamma-some assembly and through RAAS modulation, avoiding deleterious actions of RAAS in several tissues, including the lung and the brain.

P2X7 receptors in BBB permeability

The BBB protects the nervous tissue from direct contact to the blood. Endothelial cells comprise the BBB and are highly selective in consequently filtering the content that is available to neurons [121]. Endothelial cells express high levels of ACE2, which is the main mediator of SARS-CoV-2 infection. The infection and death of these cells may disrupt the barrier and let both the virus and inflammation molecules to access the nervous system (Fig. 1C).

As previously mentioned, ATP acts as a DAMP and activates the P2X7 receptor, which is largely expressed by endothelial cells and astrocytes/microglial cells, releasing pro-inflammatory cytokines and amplifying the immune response [122]. The opening of P2X7 receptor channels leads to IL-1β production mainly through NLRP3 inflammasome activation [123], thus contributing to the disruption of the BBB. In this way, SARS-CoV-2 infection can disrupt the BBB by directly infecting and killing endothelial cells, as well as by triggering P2X7 receptor signaling. In agreement, P2X7 receptor antagonism protects against BBB disruption during intracerebral hemorrhage [124]. Moreover, disruption of the BBB due to other viral infections has already been proven to trigger long-term development of neurological disorders, such as Alzheimer’s disease, depression, anxiety and multiple sclerosis [125–127].
Both intracerebral hemorrhage, against which the P2X7 receptor antagonist protects [124], and clots are responsible for the primary stroke in the brain [128]. COVID-19 patients are suffering acute cerebrovascular disorder and other correlated neurological symptoms as consequences of stroke or micro-strokes [24]. Stroke includes medical conditions that affect blood vessels of the brain, impairing cerebral circulation as consequence of damaged or deformed arteries (Fig. 2A). Diverse hospitals reported increasing levels of patients affected by stroke during SARS-CoV-2 infection [129, 130]. Klok and colleagues observed disturbing increases in the incidence of thrombotic complications in critically ill intensive care unit patients as high as 31% and recommended pharmacological prophylaxis against thrombosis [24].

The most recent hypothesis for the increased levels of strokes in COVID-19 patients is that hundreds of clots produced in the lungs due to excessive inflammation process may be transported into brain arteries, causing stroke by hypoxia. Further, the virus can access the brain through the blood stream and infect BBB cells, as observed for other viruses [131]. Both ways can lead to increased inflammation due to hypoxia, increased acidification and release of DAMPs at the niche of the injury, disrupting the BBB and damaging the CNS and, thus, leading to the development of neuropsychiatric disorders.

Neuropsychiatry and neurodegenerative disorders associated to COVID-19

As already mentioned, inflammation is mediated by cytokines, chemokines, ROS and other bioactive molecules. These molecules act like DAMPs, signaling astro- and microgliosis. The first immune response to an insult in the nervous system is the activation of microglial cells of the M2 phenotype, which is involved in anti-inflammatory mechanisms for defense and injury repair [132]. However, the sustained activation of these cells induces the phenotypic change to the M1 type, involved in pro-apoptotic processes, production and release of cytokines and ROS that could induce neurodegeneration. In fact, neuroinflammation is closely related to neurodegenerative diseases, as Huntington’s [133], Alzheimer’s [134] and Parkinson’s disease [135] and neuropsychiatric disorders, such as major depressive disorder, bipolar disorder and anxiety [136]. Since the CNS immune response is also modulated by peripheral components [137], we hypothesized that the cytokine storm induced by viral infection could stimulate neuroinflammation and neuronal death, facilitating the development of these diseases (Fig. 2B). Pathological inflammation may be induced by P2X7 receptor activation, and its antagonism has been proposed as a therapeutic approach for COVID-19 treatment [106].

The role of the P2X7 receptor in neuroinflammatory processes in neuropsychiatric and neurodegenerative diseases is widely studied [95, 118]. In neurodegenerative diseases, cell death is accompanied by neuroinflammatory processes and massive ATP release [138]. In animal models for neurodegeneration P2X7 receptor antagonism exerted beneficial anti-inflammatory effects [138, 139], indicating that P2X7 receptor activation and subsequent neuroinflammation is tightly related to neurodegeneration worsening. Experimental evidence supports that viral infection may evoke neuronal death, encephalopathy, myelin destruction and juvenile Parkinson’s disease development; however, these studies did not include coronaviruses [140]. These evidences indicate that viral infection facilitates neurodegenerative disease development, as Alzheimer’s disease, Multiple Sclerosis and Parkinson’s Disease [140]. In fact, murine coronavirus is used to induce encephalitis in mice with prominent demyelination and axonal damage. Based on observed pathophysiology and disease progression, this has been proposed as an animal model of multiple sclerosis [141].

Curiously, anosmia is one of the neurological symptoms reported by SARS-CoV-2 patients. It is worthwhile noting that olfactory impairment is an early predictor of Parkinson’s disease development due to α-synuclein aggregation in the olfactory bulb [142]. Although these symptoms might not be disease-related, studies show that α-synuclein induces mitochondrial dysfunction and microglial activation caused by P2X7 receptor stimulation [143, 144]. Further investigation of neural cell marker expression of COVID-19 patients could clarify, whether neuroinflammation is related to the observed anosmia.

Neuroinflammation and increased levels of ATP are observed in neuropsychiatry disorders, supposedly correlated with P2X7 receptor activation [118, 145]. Corroborating this hypothesis, antidepressant treatment decreased P2X7 receptor expression in the ventral hippocampus of stressed animals [146]. Moreover, the treatment with a selective P2X7 receptor antagonist (A-804598) induced antidepressant-like effect associated with inflammasome stimulation [147] and BDNF signaling activation [148] in rodent hippocampus. In this context, we propose that the cytokine storm and cell death induced by SARS-CoV-2 infection results in P2X7 receptor-mediated neuroinflammation, leading to the development of neuropsychiatric disorders. Noteworthy, the P2X7 receptor antagonist IN-54175446 is undergoing clinical trials with treatment-resistant depressive patients (EudraCT number 2018-001884-21 at www.clinicaltrialsregister.eu).

As mentioned, a study with 714 patients with COVID-19 found a prevalence of self-reported post-traumatic stress disorder symptoms in 96.2% of them [149]. Another study with 114 patients reported that 34.7% of patients presented anxiety symptoms, while 28.5% of them displayed...
Depression symptoms [150]. Moreover, COVID-19 related psychiatric symptoms (including anger, anxiety, suicidal ideas, hallucinations, insomnia, impaired memory, poor concentration, time disorientation, fear/panic, pressured speech, mood alterations, pessimistic thinking, crying spell and persecutory ideas) have been largely described during and after the occurrence of other respiratory pandemics, such as MERS [151] and SARS [152–159]. Further indication for psychiatric implications of coronaviruses infections came from a study of Okusaga et al. [160], who connected seropositivity for human coronavirus strain L63 with mood disorders and suicide attempts. The study could come to a limited conclusion, as it would need to be conducted with more control and coronavirus-serum positive volunteers. However, the authors of this study distinguished between two possible scenarios, which might be important for the understanding of neuronal effects of COVID-19: (1) the connection between depression and immune responses with possible pro-inflammatory interleukin overshooting, which may trigger oxidative stress and neuroinflammation as part of the causes of psychiatric disorders; and (2) viral infection acting as a form of stress. Dysregulated stress and neuroinflammatory responses might cause hypothalamic–pituitary–adrenal (HPA) axis dysfunction. Alterations in the HPA axis have been linked to mood diseases, and HPA activation has been connected with suicide. Hiroi et al. found hyperplastic adrenals in suicide victims, corroborating with such hypothesis [161]. In line, a small COVID-19 patients’ study concluded that preexisting psychiatric disease patients reported mental symptom worsening following infection with the virus [162].

Noteworthy, gene knockout or pharmacological inhibition of P2X7 receptors induced antidepressant-like behavior in mice exposed to stress, accompanied by HPA axis restoration [163, 164]. This axis is also activated for counteracting tissue damage, evoked by cytokine storms, in SARS-CoV-2 infection, as previously reviewed [165]. Thus, the HPA axis might provide a connection between coronaviruses and psychiatric disorders. Noteworthy, such mechanism would explain the possible propensity for the development of mood disorders triggered by COVID-19 infection as well as raise the hypothesis that mood disorder patients might be more prone to severe COVID-19 disease development. These patients already carry augmented inflammation patterns, such as systemic inflammation, or suffer from a cytokine storm [166] and show enhanced P2X7 receptor expression, as previously discussed. However, a wide variety of responses to SARS-CoV-2 infection are not yet understood. Further studies are needed to elucidate genetic and environmental factors that could affect individual vulnerability to COVID-19 infection.

Finally, increasing VEGF concentrations, which recruit inflammatory cells into the brain and sustain neuroinflammation, have been named as target for COVID-19 treatment [167]. The COVID-19 entry receptor ACE2 activates RAAS for neuroinflammation and VEGF synthesis by Ang II binding to AT1R (reviewed in ref. [167]). Besides ACE2, aberrant P2X7 receptor activation also induces VEGF release and signaling in the brain [168]. Thus, although VEGF involvement in major depressive disorder is controversially discussed [169, 170], this growth factor could be involved in the connection between COVID-19, major depressive disorder and purinergic signaling.

**Conclusion**

Several lines of evidence have raised the possibility of neuroinvasion by SARS-CoV-2 (Fig. 1), which may cause short- or long-term impairment of the CNS. The main mechanism involved in this scenario is neuroinflammation, a critical process in psychiatric and neurodegenerative disease development. SARS-CoV-2 infection induces a cytokine storm that could trigger and/or worse neuroinflammatory processes. Patients with mental disorders associated to neuroimmune activation such as depression, Parkinson’s or Alzheimer’s disease may also present increased susceptibility to SARS-CoV-2 infection and/or severe disease development. Neuroimmune response hyperstimulation observed during viral infection and in mental disorders may be mediated by P2X7 receptor activation (Fig. 2). In view of that, we suggest P2X7 receptor as a key mediator of the neuroinflammatory process as a possible consequence of SARS-CoV-2 infection. In this context, P2X7 receptor antagonism could be a promising strategy to avoid and treat psychiatric disorders and neurodegenerative diseases of COVID-19 patients.

**Acknowledgements** HU and CL acknowledge grant support from the São Paulo Research Foundation (FAPESP, Project No. 2015/19128-2 and 2018/07366-4). HU acknowledges the National Council for Scientific and Technological Development for fellowship support (CNPq, Project No. 306392/2017-8). MZR work was supported by the NIH grant 2R01 DK074720, the Stella and Henry Hoenig Endowment. DER, AO-G, and TG are grateful for postdoctoral fellowships granted by FAPESP (Project No. 2018/17504-5, 2019/26852-0, and 2015/13345-1-PD, respectively). VFA-S thanks CNPq for a doctoral fellowship (Project No. 141264/2017-9). RA is grateful for a doctoral fellowship from FAPESP (Project No. 2019/24553-5) and JB for the doctoral fellowship granted by CNPq (Project No. 142137/2019-7).

**Compliance with ethical standards**

**Conflict of interest** The authors declare that they have no conflict of interest.
Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

1. Walls AC, Park Y-J, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181:281–92.
2. Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 2020;5:562–9.
3. Wang K, Chen W, Zhou Y-S, Lian J-Q, Zhang Z, Du P, et al. SARS-CoV-2 invades host cells via a novel route: CD147-spike protein. 2020. https://doi.org/10.1101/2020.03.14.988345.
4. Ulrich H, Pillatt MM. CD147 as a target for COVID-19 treatment: suggested effects of azithromycin and stem cell engagement. Stem Cell Rev Rep. 2020;2020:1–7.
5. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger T, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–80.e8.
6. Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020;11:1620.
7. Ratajczak J, Wysoczynski M, Hayek F, Janow ska-Wieczorek A, Kucia M, et al. ATP-Nlrp3 inflammasome as a rising star in studies of normal and malignant hematopoiesis. Leukemia. 2020;34:1512–23.
8. Sauty R. The P2X7 receptor. In: Atassi M, editor. Protein reviews. Advances in experimental medicine and biology. Singapore: Springer; 2017. p. 17–53.
9. Adinolfi E, Giuliani AL, De Marchi E, Pegoraro A, Orioli E, Di Virgilio F. The P2X7 receptor: a main player in inflammation. Biochem Pharmacol. 2018;151:234–44.
10. Sperlágh B, Illes P. P2X7 receptor: An emerging target in central nervous system diseases. Trends Pharm Sci. 2014;35:537–47.
11. Pezzini A, Padovani A. Lifting the mask on neurological manifestations of COVID-19. Nat Rev Neurol. 2020;16:636–44.
12. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–7.
13. Butwot R, Bilinska K. SARS-CoV-2: olfaction, brain infection, and the urgent need for clinical samples allowing earlier virus detection. ACS Chem Neurosci. 2020;11:1200–3.
14. Puelles VG, Lütgheat mitt J, Lindenmeyer MT, Sperhake JP, Wong MN, Allweiss L, et al. Multiorgan and renal tropism of SARS-CoV-2 [letter]. N Engl J Med. 2020;383:590–92.
15. Song E, Zhang C, Israelow B, Lu-Culligan A, Prado AV, Skriabine S, et al. Neuroinvasion of SARS-CoV-2 in human and mouse brain. 2020. https://doi.org/10.1101/2020.06.25.169994.
16. Gomes IC, Karmirian K, Oliveira J, Pedrosa C, Rosman FC, Chimelli LR, et al. SARS-CoV-2 infection in the central nervous system of a 1-year-old infant submitted to complete autopsy. 2020;202009297. https://doi.org/10.20944/preprints202009.0297.v1.
17. Paniz-Mondolfi A, Bryce C, Grimes Z, Gordon RE, Reidy J, Lednicky J, et al. Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). J Med Virol. 2020;92:699–702.
18. Aragoneza D, Alfonso E, Clayton AH. The blood–brain barrier and the role of cytokines in neuropsychiatry. Psychiatry. 2009;6:18–22.
19. Pan W, Stone KP, Hsouchou H, Manda VK, Zhang Y, Kastin AJ. Cytokine signaling modulates blood–brain barrier function. Curr Pharm Des. 2011;17:3729–39.
20. Lin YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV-2 in the central nervous system of a 1-year-old infant submitted to complete autopsy. 2020;202009297. https://doi.org/10.20944/preprints202009.0297.v1.
21. Yarlagadda L, Tuberosa J, Rossier D, Carleton A, Bryce C, Grimes Z, Gordon RE, Reidy J, Lednicky J, et al. Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). J Med Virol. 2020;92:699–702.
22. Fodoulian L, Tuberosa J, Rossier D, Landis B, Carleton A, Bryce C, Grimes Z, Gordon RE, Reidy J, Lednicky J, et al. Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). J Med Virol. 2020;92:699–702.
23. Brann DH, Tsukahara T, Weinreb C, Lipovsek M, Van den Berge K, Gong B, et al. SARS-CoV-2 invades host cells via a novel route: CD147-spike protein. 2020. https://doi.org/10.1101/2020.03.31.013268.
24. Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 2020;5:562–9.
25. Sperlágh B, Illes P. P2X7 receptor: An emerging target in central nervous system diseases. Trends Pharm Sci. 2014;35:537–47.
26. Pezzini A, Padovani A. Lifting the mask on neurological manifestations of COVID-19. Nat Rev Neurol. 2020;16:636–44.
27. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–7.
28. Butwot R, Bilinska K. SARS-CoV-2: olfaction, brain infection, and the urgent need for clinical samples allowing earlier virus detection. ACS Chem Neurosci. 2020;11:1200–3.
29. Puelles VG, Lütgheatmitt J, Lindenmeyer MT, Sperhake JP, Wong MN, Allweiss L, et al. Multiorgan and renal tropism of SARS-CoV-2 [letter]. N Engl J Med. 2020;383:590–92.
30. Song E, Zhang C, Israelow B, Lu-Culligan A, Prado AV, Skriabine S, et al. Neuroinvasion of SARS-CoV-2 in human and mouse brain. 2020. https://doi.org/10.1101/2020.06.25.169994.
31. Spindler KR, Hsu TH. Viral disruption of the blood–brain barrier function. Curr Pharm Des. 2011;17:3729–39.
32. Lin YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV-2 in the central nervous system of a 1-year-old infant submitted to complete autopsy. 2020;202009297. https://doi.org/10.20944/preprints202009.0297.v1.
33. Paniz-Mondolfi A, Bryce C, Grimes Z, Gordon RE, Reidy J, Lednicky J, et al. Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). J Med Virol. 2020;92:699–702.
34. Brann DH, Tsukahara T, Weinreb C, Lipovsek M, Van den Berge K, Gong B, et al. SARS-CoV-2 invades host cells via a novel route: CD147-spike protein. 2020. https://doi.org/10.1101/2020.03.31.013268.
35. Brann DH, Tsukahara T, Weinreb C, Lipovsek M, Van den Berge K, Gong B, et al. Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia. Sci Adv. 2020;6:eabc5801.
36. Fodoulian L, Tuberosa J, Rossier D, Landis B, Carleton A, Rodriguez I. SARS-CoV-2 receptor and entry genes are expressed by sustentacular cells in the human olfactory neuroepithelium. 2020. https://doi.org/10.1101/2020.03.31.013268.
37. Brann DH, Tsukahara T, Weinreb C, Lipovsek M, Van den Berge K, Gong B, et al. Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia. Sci Adv. 2020;6:eabc5801.
38. McCray PB, Pelew L, Wohlford-Lenane C, Hickey M, Manzel L, Shi L, et al. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J Virol. 2007;81:813–21.
39. Jacomy H, Talbot PJ. Vacuolating encephalitis in mice infected by human coronavirus OC43. Virology. 2003;315:20–33.
40. Li K, Wohlford-Lenane C, Perlman S, Zhao J, Jewell AK, Reznikov LR, et al. Middle east respiratory syndrome coronavirus causes multiple organ damage and lethal disease in
mice transgenic for human dipeptidyl peptidase 4. J Infect Dis. 2016;213:712–22.
38. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8:420–2.
39. Bhata M, Zemans RL, Jayaseelan S. Role of chemokines in the pathogenesis of acute lung injury. Am J Respir Cell Mol Biol. 2012;46:566–72.
40. Dunkelberger JR, Song WC. Complement and its role in innate and adaptive immune responses. Cell Res. 2010;20:34–50.
41. Swanson KV, Deng M, Ting JP. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019;19:477–89.
42. Bertheloot D, Latz E. HMGB1, IL-1alpha, IL-33 and S100 proteins: dual-function alarmins. Cell Mol Immunol. 2017;14:43–64.
43. Kai H, Kai M. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors—lessons from available evidence and insights into COVID-19. Hypertens Res. 2020;43:648–54.
44. Albalawi F, Lu W, Beckel JM, McLaughey SA, Mitchell CH. The P2X7 receptor primes IL-1beta and the NLRP3 inflammasome in astrocytes exposed to mechanical strain. Front Cell Neurosci. 2017;11:227.
45. Nascimento JHP, Gomes BF, de O, Do Carmo Júnior PR, Petriz JLF, Rizk SI, et al. Covid-19 and hypercoagulable state: a new therapeutic perspective. Arq Bras Cardiol. 2020;114:829–33.
46. Ratatzczak MZ, Pedziwiatr D, Cymer M, Kucia M, Kucharska-Mazur J, Samochowiec J. Sterile inflammation of brain, due to activation of innate immunity, as a culprit in psychiatric disorders. Front Psychiatry. 2018;9:60.
47. Burnstock G, Kennedy C. P2X receptors in health and disease. In: Advances in pharmacology, vol. 61. Academic Press Inc; 2011. p. 333–72.
48. Janks L, Sprague RS, Egan TM. ATP-gated P2X7 receptors require chloride channels to promote inflammation in human macrophages. J Immunol. 2019;202:883–98.
49. Chen Z, Jin N, Narasaruja T, Chen J, McFarland LR, Scott M, et al. Identification of two novel markers for alveolar epithelial type I and II cells. Biochem Biophys Res Commun. 2004;319:774–80.
50. Kaczmarek-Hajek K, Zhang J, Kopp R, Grosche A, Rissiek B, Saul A, et al. Re-evaluation of neuronal P2X7 expression using novel mouse models and a P2X7-specific nanobody. Elife. 2018;7:1–29.
51. Metzger MW, Walser SM, Aprile-Garcia F, Dedic N, Chen A, Holboer F, et al. Genetically dissecting P2X7 expression within the central nervous system using conditional humanized mice. Purinergic Signal. 2017;13:153–70.
52. He Y, Taylor N, Fourgeaud L, Bhattacharya A. The role of microglial P2X7: modulation of cell death and cytokine release. J Neuroinflammation. 2017;14:135.
53. Sperliagh B, Köfalfi A, Deuchars J, Atkinson L, Milligan CJ, Buckley NJ, et al. Involvement of P2X7 receptors in the regulation of neurotransmitter release in the rat hippocampus. J Neurochem. 2002;81:1196–211.
54. Wirkner K, Köfalfi A, Fischer W, Günther A, Franke H, Gröger-Arndt H, et al. Supersensitivity of P2X7 receptors in cerebrocortical cell cultures after in vitro ischemia. J Neurochem. 2005;95:1421–37.
55. Yu Y, Ugawa S, Ueda T, Ishida Y, Inoue K, Kyaw Nyunt A, et al. Cellular localization of P2X7 receptor mRNA in the rat brain. Brain Res. 2008;1194:45–55.
56. Anderson CM, Nedergaard M. Emerging challenges of assigning P2X7 receptor function and immunoreactivity in neurons. Trends Neurosci. 2006;29:257–62.
57. Illes P, Khan TM, Rubini P. Neuronal P2X7 receptors revisited: do they really exist? J Neurosci. 2017;37:7049–62.
58. Khan MT, Deussing J, Tang Y, Illes P. Astrocytic rather than neuronal P2X7 receptors modulate the function of the tri-synaptic network in the rodent hippocampus. Brain Res Bull. 2018;151:164–73.
59. Fischer W, Appelt K, Grohmann M, Franke H, Nörenberg W, Illes P. Increase of intracellular Ca2+ by P2X2 and P2Y receptor subtypes in cultured cortical astroglia of the rat. Neuroscience. 2009;160:767–83.
60. Rubini P, Pagel G, Mehri S, Marquardt P, Riedel T, Illes P. Functional P2X7 receptors at cultured hippocampal astrocytes but not neurons. Naunyn Schmiedebergs Arch Pharm. 2014;387:943–54.
61. Ratajczak MZ, Kucia M. SARS-CoV-2 infection and over-activation of Nlrp3 inflammasome as a trigger of cytokine “storm” and risk factor for damage of hematopoietic stem cells. Leukemia. 2020;34:1726–9.
62. Chessell IP, Michel AD, Humphrey PPA. Properties of the pore-forming P2X7 purinoceptor in mouse NTW8 microglial cells. Br J Pharm. 1997;121:1429–37.
63. Chessell IP, Michel AD, Humphrey PPA. Effects of antagonists at the human recombinant P2X7 receptor. Br J Pharm. 1998;124:1314–20.
64. Di Virgilio F, Schmalzing G, Markwardt F. The elusive P2X7 macroure. Trends Cell Biol. 2018;28:392–404.
65. Kopp R, Krautloher A, Ramirez-Fernandez A, Nicke A. P2X7 interactions and signaling—making head or tail of it. Front Mol Neurosci. 2019;12:1–25.
66. Sluyter R, Stokes L. Significance of p2x7 receptor variants to human health and disease. Recent Pat DNA Gene Seq. 2011;5:41–54.
67. Falzoni S, Donvito G, Di Virgilio F. Detecting adenosine triphosphate in the pericellular space. Interface Focus. 2013;3:20120101.
68. Pellegratti P, Raffaghello L, Bianchi G, Piccardi F, Pistoia V, Di Virgilio F. Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase. PLoS ONE. 2008;3:e2599.
69. Wilhelm K, Ganesan J, Grimm M, Bechich A, Krempdl C, Sorichter S, et al. Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R. Nat Med. 2010;16:1434–9.
70. Barberà G, Sorichter S, et al. Humanizing mice transgenic for human dipeptidyl peptidase 4. J Infect Dis. 2005;174:7268–72.
71. Jo EK, Kim JK, Shin DM, Sasakawa C. Molecular mechanisms regulating NLRP3 in human health and disease. Front Cell Neurosci. 2019;12:1–25.
72. García Y, Roso S, Manresa N, García M, García MG. COVID-19 associated with acute respiratory failure and cytokine storm: a single-center experience. J Intern Med. 2020;287:164–72.
73. Chessell IP, Michel AD, Humphrey PPA. Effects of antagonists at the human recombinant P2X7 receptor. Br J Pharm. 1998;124:1314–20.
74. Pellegratti P, Raffaghello L, Bianchi G, Piccardi F, Pistoia V, Di Virgilio F. Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase. PLoS ONE. 2008;3:e2599.
75. Wilhelm K, Ganesan J, Grimm M, Bechich A, Krempdl C, Sorichter S, et al. Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R. Nat Med. 2010;16:1434–9.
76. Barberà-Gremades M, Baroja-Mazo A, Gomez Al, Machado F, Di Virgilio F, Pelegrin P. P2X7 receptor-stimulation causes fever via PGE2 and IL-1β release. FASEB J. 2012;26:2951–62.
77. Jo EK, Kim JK, Shin DM, Sasakawa C. Molecular mechanisms regulating NLRP3 inflammasome activation. Cell Mol Immunol. 2016;13:148–59.
78. Gustin A, Kirchmeyer M, Koncina E, Felten P, Loscuito S, Heurtaux T, et al. NLRP3 inflammasome is expressed and functional in mouse brain microglia but not in astrocytes. PLoS ONE. 2015;10:1–19.
79. Bhattacharya A, Jones DNC. Emerging role of the P2X7-NLRP3-IL1β pathway in mood disorders. Psychoneuroendocrinology. 2018;98:95–100.
80. Perregea DG, Gabel CA. Human monocyte stimulus-coupled IL-1β posttranslational processing: modulation via monovalent cations. Am J Physiol - Cell Physiol. 1998;275:C1538–47.
81. Qu Y, Franchi L, Nunez G, Dubayk GR. Nonclassical IL-1 beta secretion stimulated by P2X7 receptors is dependent on inflammasome activation and correlated with exosome release in murine macrophages. J Immunol. 2007;179:1913–25.
82. Bianco F, Pravettoni E, Colombo A, Schenk U, Möller T, Matteoli M, et al. Astrocyte-derived ATP induces vesicle shedding and IL-1β release from microglia. J Immunol. 2005;174:7268–77.
Hyperactivation of P2X7 receptors as a culprit of COVID-19 neuropathology

77. Kataoka A, Torzaki-Saitoh H, Koga Y, Tsuda M, Inoue K. Activation of P2X7 receptors induces CCL3 production in microglial cells through transcription factor NFAT. J Neurochem. 2009;108:115–25.

78. Suzuki T, Hida I, Ido K, Kohsaka S, Inoue K, Nakata Y. Production and release of neuroprotective tumor necrosis factor by P2X7 receptor-activated microglia. J Neurosci. 2004;24:1–7.

79. Shieh CH, Heinrich A, Serchov T, van Calker D, Biber K. P2X7-dependent, but differentially regulated release of IL-6, CCL2, and TNF-α in cultured mouse microglia. Glia. 2014;62:592–607.

80. Shiratori M, Tozaki-Saitoh H, Yoshitake M, Tsuda M, Inoue K. P2X7 receptor activation induces CXCCL2 production in microglia through NFAT and PKC/MAPK pathways. J Neurochem. 2010;114:810–9.

81. Morandini A, Savio L, Coutinho-Silva R. The role of p2x7 receptor in infectious inflammatory diseases and the influence of ectonucleotidases. Biomed J. 2014;37:169–77.

82. Savio LEB, Mello P de A, da Silva CG, Coutinho-Silva R. The P2X7 receptor in inflammatory diseases: angel or demon? Front Pharmacol. 2018;9:1–31.

83. Martínez-García J, Martínez-Banaclocha H, Angosto-Bazarra D, De Torre-Minguera C, Baroja-Mazo A, Alarcón-Vila C, et al. P2X7 receptor induces mitochondrial failure in monocytes and compromises NLRP3 inflammasome activation during sepsis. Nat Commun. 2019;10:1–14.

84. Savio LEB, Juste Andrade MG, de Andrade Mello P, Teixeira Santana P, Cristina Abreu Moreira-Souza A, Kolling J, et al. P2X7 receptor signaling contributes to sepsis-associated brain dysfunction. Mol Neurobiol. 2017;54:6459–70.

85. Cheesell JP, Hatcher JP, Bountra C, Michel AD, Hughes JP, Green P, et al. Disruption of the P2X7 purinoreceptor gene abolishes chronic inflammatory and neuropathic pain. Pain. 2005;114:386–96.

86. Yip L, Woehrle T, Corriden R, Hirsh M, Chen Y, Inoue Y, et al. Autocrine regulation of T-cell activation by ATP release and P2X7 receptors. FASEB J. 2009;23:1685–93.

87. Galam L, Rajan A, Failla A, Soundararajan R, Lockey RF, Kolliputi N. Deletion of P2X7 attenuates hyperoxia-induced acute lung injury via inflammasome suppression. Am J Physiol - Lung Cell Mol Physiol. 2016;310:572–81.

88. Duan L, Hu Ghuang, Li Yjin, Zhang Liang, Jiang M. P2X7 receptor is involved in lung injuries induced by ischemia-reperfusion in pulmonary arterial hypertension rats. Mol Immunol. 2018;101:409–18.

89. Riteau N, Gasse P, Fauconnier L, Gombault A, Couegnat M, Arnaud-Sampaio VF, Lameu C, et al. The P2X7 receptor: central and TNF-α dependent, but differentially regulated release of IL-6, CCL2, and TNF-α in cultured mouse microglia. Glia. 2014;62:592–607.

90. Wang S, Zhao J, Wang H, Liang Y, Yang N, Huang Y. Blockage of P2X7 attenuates acute lung injury in mice by inhibiting NLPR3 inflammasome. Int Immunopharmacol. 2015;27:38–45.

91. Liu T, Wang J, Li R, Zhu F, Xu W, Zha G, et al. ATP/P2X7-NLPR3 axis of dendritic cells participates in the regulation of airway inflammation and hyper-responsiveness in asthma by mediating HMGB1 expression and secretion. Exp Cell Res. 2018;366:1–15.

92. Cheffer A, Castillo AR, Corrêa-Velloso JC, Gonçalves MCB, Naaldijk Y, Nascimento IC, et al. Purinergic system in psychiatric diseases. Mol Psychiatry. 2018;23:94–106.

93. Bhattacharya A, Biber K. The microglial ATP-gated ion channel P2X7 as a CNS drug target. Glia. 2016;64:1772–87.

94. Burnstock G. Purinergic signalling and neurological diseases: an update. CNS Neurol Disord - Drug Targets. 2017;16:257–65.

95. Andrejew R, Oliveira-Giacomelli A, Ribeiro DE, Glaser T, Arnaud-Sampaio VF, Lameu C, et al. The P2X7 receptor: central hub of brain diseases. Front Mol Neurosci. 2020;13:124.

96. Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG. Into the eye of the cytokine storm. Microbiol Mol Biol Rev. 2012;76:16–32.

97. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J Infect. 2020;80:607–13.

98. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.

99. Yang Y, Chen S, Li J, Yuan J, Wei J, Huang F, et al. Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19. J Allergy Clin Immunol. 2020;146:119–27.

100. Pedersen SF, Ho YC. SARS-CoV-2: a storm is raging. J Clin Invest. 2020;130:2202–5.

101. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130:2620–9.

102. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Disregulation of immune response in patients With COVID-19 in Wuhan, China. Clin Infect Dis. 2020;71:762–8.

103. Gao Y, Li T, Han M, Li X, Wu D, Xu Y, et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol. 2020;92:791–6.

104. Liu T, Zhang J, Yang Y, Ma H, Li Z, Zhang J, et al. The role of interleukin-6 in monitoring severe case of coronavirus disease 2019. EMBO Mol Med. 2020;12:e12421.

105. Zhang C, He H, Wang L, Zhang H, Huang H, Xiong Q, et al. Virus-triggered ATP release limits viral replication through facilitating IFN-β production in a P2X7-dependent manner. J Immunol. 2017;199:1372–81.

106. Graziano F, Desdouits M, Garzetti L, Podini P, Alfano M, Rubartelli A, et al. Extracellular ATP induces inflammatory and functional pulmonary changes induced by silica. PLoS ONE. 2014;9:e110185.

107. Zhang C, He H, Wang L, Zhang H, Huang H, Xiong Q, et al. Virus-triggered ATP release limits viral replication through facilitating IFN-β production in a P2X7-dependent manner. J Immunol. 2017;199:1372–81.

108. Graziano F, Desdouits M, Garzetti L, Podini P, Alfano M, Rubartelli A, et al. Extracellular ATP induces the rapid release of HIV-1 from virus containing compartments of human macrophages. Proc Natl Acad Sci U S A. 2015;112:E3265–73.

109. Levy-Graado VH, Ermler ME, Schotsaert M, Gonzalez MG, Gillespie V, Lim JK, et al. Contribution of the purinergic receptor P2X7 to development of lung immunopathology during influenza virus infection. MBio. 2017;8:1–15.

110. Lee BH, Whang DM, Palaniyar N, Grinstein S, Philpott DJ, Hu J. Activation of P2X(7) receptor by ATP plays an important role in regulating inflammatory responses during acute viral infection. PLoS ONE. 2012;7:e35812.

111. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46:586–90.

112. Pillat MM, Krüger A, Guimarães LMF, Lameu C, de Souza EE, Pillat MM, et al. Insights in chloroquine action: perspectives and implications in Malaria and COVID-19. CytoM Part A. 2020;97:872–81.

113. Wang J, Chen L, Chen B, Meliton A, Liu SQ, Shi Y, et al. Chronic activation of the renin-angiotensin system induces lung fibrosis. Sci Rep. 2015;5:15561.

114. Gironacci MM, Vicario A, Cerezo G, Silva MG. The depressor effect of the renin-angiotensin system and brain disorders: A translational approach. Clin Sci. 2018;132:1021–38.
Hyperactivation of P2X7 receptors as a culprit of COVID-19 neuropathology

153. Chua SE, Cheung V, McAlonan GM, Cheung C, Wong JWS, Cheung EPT, et al. Stress and psychological impact on SARS patients during the outbreak. Can J Psychiatry. 2004;49:385–90.

154. Lee AM, Wong JGWS, McAlonan GM, Cheung V, Cheung C, Sham PC, et al. Stress and psychological distress among SARS survivors 1 year after the outbreak. Can J Psychiatry. 2007;52:233–40.

155. Sheng B, Cheng SKW, Kwok KL, Ho LL, Chan ELY. The effects of disease severity, use of corticosteroids and social factors on neuropsychiatric complaints in severe acute respiratory syndrome (SARS) patients at acute and convalescent phases. Eur Psychiatry. 2005;20:236–42.

156. Cheng SKW, Wong CW, Tsang J, Wong KC. Psychological distress and negative appraisals in survivors of severe acute respiratory syndrome (SARS). Psychol Med. 2004;34:1187–95.

157. Mak IWC, Chu CM, Pan PC, Yiu MGC, Chan VL. Long-term psychiatric morbidities among SARS survivors. Gen Hosp Psychiatry. 2009;31:318–26.

158. Hong X, Currier GW, Zhao X, Jiang Y, Zhou W, Wei J. Post-traumatic stress disorder in convalescent severe acute respiratory syndrome patients: a 4-year follow-up study. Gen Hosp Psychiatry. 2009;31:546–54.

159. Lam MHB, Wing YK, Yu MWM, Leung CM, Ma RCW, Kong APS, et al. Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors long-term follow-up. Arch Intern Med. 2009;169:2142–7.

160. Okusaga O, Volken RH, Langenberg P, Lapidus M, Arling TA, Dickerson FB, et al. Association of seropositivity for influenza and coronaviruses with history of mood disorders and suicide attempts. J Affect Disord. 2011;130:220–5.

161. Hiroi N, Wong ML, Licinio J, Park C, Young M, Gold PW, et al. Expression of corticotropin releasing hormone receptors type I and type II mRNA in suicide victims and controls. Mol Psychiatry. 2001;6:540–6.

162. Vindegaard N, Eriksen Benros M. COVID-19 pandemic and mental health consequences: systematic review of the current evidence. Brain Behav Immun. 2020;89:531–42.

163. Farooq RK, Tanti A, Ainouche S, Roger S, Belzung C, Camus M. The psychological impact of coronavirus disease 2019 (COVID-19) on medical healthcare workers and COVID-19 patients amidst the COVID-19 pandemic: a systematic review and meta-analysis. Psychiatry Res. 2020;293:113382.

164. Xiong J, Lipsitz O, Narsi F, Lui LMW, Gill H, Phan L, et al. Impact of COVID-19 pandemic on mental health in the general population: a systematic review. J Affect Disord. 2020;275:55–64.

165. de Silva FCT, Neto MLR. Psychological effects caused by the COVID-19 pandemic in health professionals: a systematic review with meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2021;104:110062.

166. Saleti N, Hosseinion-Far A, Jalali R, Vaisi-Raygani A, Rasoulpour S, Mohammed M, et al. Prevalence of stress, anxiety, depression among the general population during the COVID-19 pandemic: a systematic review and meta-analysis. Glob Health. 2020;16:57.

167. de Pablo GS, Vaquerizo-Serrano J, Catalan A, Arango C, Moreno C, Ferre F, et al. Impact of coronavirus syndromes on physical and mental health of health care workers: systematic review and meta-analysis. J Affect Disord. 2020;275:48–57.

168. Luo M, Guo L, Yu M, Wang H. The psychological and mental impact of coronavirus disease 2019 (COVID-19) on medical staff and general public—a systematic review and meta-analysis. Psychiatry Res. 2020;291:113190.